Coloncancer, nye behandlingsprinsipper
- Prosjektnummer
- 2004141
- Ansvarlig person
- Kjell Magne Tveit
- Institusjon
- Ullevål universitetssykehus HF
- Prosjektkategori
- Fritt forskningsprosjekt
- Helsekategori
- Oncogenesis & Cancer Research
- Forskningsaktivitet
- Laboratoriebasert somatisk
Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study.
BMC Cancer 2006;6():67. Epub 2006 mar 16
PMID: 16542436
Increased mRNA expression levels of ERCC1, OGG1 and RAI in colorectal adenomas and carcinomas.
BMC Cancer 2006;6():208. Epub 2006 aug 16
PMID: 16914027
Effects of polymorphisms in ERCC1, ASE-1 and RAI on the risk of colorectal carcinomas and adenomas: a case control study.
BMC Cancer 2006;6():175. Epub 2006 jul 3
PMID: 16817948
Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma.
BMC Cancer 2007;7():192. Epub 2007 okt 12
PMID: 17935612
Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas.
BMC Cancer 2007;7():228. Epub 2007 des 19
PMID: 18093316
Prostaglandins enhance epidermal growth factor-induced DNA synthesis in hepatocytes by stimulation of E prostanoid 3 and F prostanoid receptors.
J Pharmacol Exp Ther 2007 Sep;322(3):1044-50. Epub 2007 jun 13
PMID: 17567965
Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes.
J Cell Physiol 2008 Feb;214(2):371-80.
PMID: 17654493
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
Ann Oncol 2008 Feb. Epub 2008 feb 14
PMID: 18281265
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
Ann Oncol 2008 Jan. Epub 2008 jan 21
PMID: 18209013
Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.
Acta Oncol 2007;46(7):982-8.
PMID: 17917829
[Multimodal treatment in colorectal cancer]
Tidsskr Nor Laegeforen 2007 Nov;127(23):3055.
PMID: 18049492
[Colorectal cancer registry]
Tidsskr Nor Laegeforen 2007 Nov;127(21):2834-5.
PMID: 17987076
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
Acta Oncol 2005;44(8):904-12.
PMID: 16332600
[Antineoplastic agents targeting tyrosine kinases]
Tidsskr Nor Laegeforen 2005 Nov;125(22):3115-9.
PMID: 16299568
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
Ann Oncol 2006 Feb;17(2):252-8. Epub 2005 nov 15
PMID: 16291583
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport